BASF PHARMA BELGIUM: what changed
What changed
BASF PHARMA BELGIUM
filed annual accounts (NBB)
Net result for the year
€183,245
2024 · €337,113-€153,867
Equity
€11.6m
2024 · €11.4m+€183,245
Cash
-
not filed
Balance sheet total
€11.6m
2024 · €11.5m+€178,336
Largest movements
Assets
- Receivables within one year +€178,336
up €178,336 (+1.6%), from €11.5m to €11.6m
of which Other amounts receivable: +€178,336
Equity and liabilities
- Profit (loss) carried forward +€183,245
up €183,245 (+0.5%), from -€36.6m to -€36.4m
Income statement
- Financial income -€160,747
down €160,747 (-39.0%), from €412,553 to €251,806
Change in the result, 2024 to 2025
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Result 2024
€337,113
Other operating charges
-€280
Other operating items
+€7,160
Financial income
-€160,747
Result 2025
€183,245
lowers the resultnot broken down further in the accounts
Derived cash bridge
Cash or the result is not a separate line in both sets of accounts. So the cash flow cannot be derived from them.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €11,469,062 | €11,647,398 | +€178,336 | +1.6% |
| Current assets | 29/58 | €11,469,062 | €11,647,398 | +€178,336 | +1.6% |
| Amounts receivable within one year | 40/41 | €11,469,062 | €11,647,398 | +€178,336 | +1.6% |
| Trade receivables | 40 | €0 | - | = | |
| Other amounts receivable | 41 | €11,469,062 | €11,647,398 | +€178,336 | +1.6% |
| Total equity and liabilities | 10/49 | €11,469,062 | €11,647,398 | +€178,336 | +1.6% |
| Equity | 10/15 | €11,444,955 | €11,628,201 | +€183,245 | +1.6% |
| Contributions | 10/11 | €48,000,000 | €48,000,000 | = | 0.0% |
| Capital | 10 | €48,000,000 | €48,000,000 | = | 0.0% |
| Issued capital | 100 | €48,000,000 | €48,000,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€36,555,045 | -€36,371,799 | +€183,245 | +0.5% |
| Amounts payable | 17/49 | €24,107 | €19,198 | -€4,909 | -20.4% |
| Amounts payable within one year | 42/48 | €24,107 | €19,198 | -€4,909 | -20.4% |
| Trade debts | 44 | €24,107 | €19,198 | -€4,909 | -20.4% |
| Suppliers | 440/4 | €24,107 | €19,198 | -€4,909 | -20.4% |
| Operating charges | 60/66A | €75,440 | €68,561 | -€6,879 | -9.1% |
| Services and other goods | 61 | €74,112 | €66,952 | -€7,160 | -9.7% |
| Other operating charges | 640/8 | €1,328 | €1,609 | +€280 | +21.1% |
| Operating profit (loss) | 9901 | -€75,440 | -€68,561 | +€6,879 | +9.1% |
| Financial income | 75/76B | €412,553 | €251,806 | -€160,747 | -39.0% |
| Recurring financial income | 75 | €412,553 | €251,806 | -€160,747 | -39.0% |
| Income from current assets | 751 | €412,553 | €251,806 | -€160,747 | -39.0% |
| Profit (loss) for the period before taxes | 9903 | €337,113 | €183,245 | -€153,867 | -45.6% |
| Profit (loss) for the period | 9904 | €337,113 | €183,245 | -€153,867 | -45.6% |
| Profit (loss) for the period to be appropriated | 9905 | €337,113 | €183,245 | -€153,867 | -45.6% |
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Compare this company with its sector.Sector benchmark
Calculation and sources
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. Prepared on 4 November 2026 via checked.be.